IP Library Granted Patent US 11,123,280
Granted Patent B2
US 11,123,280 · App. 15/909,991 · Granted Sep 21, 2021

Method of assessing and treating cellulite

Inventors: Jeffrey Davidson (Downingtown, PA); Michael McLane (Lansdale, PA); Genzhou Liu (North Wales, PA)
Assignee: ENDO VENTURES LIMITED
A61K8/66A61B5/103A61B5/44A61B5/441A61B5/444A61B5/4848A61K38/4886A61Q19/06C12Y304/24003A61B5/1079
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,123,280
App. No.
15/909,991
Granted
Sep 21, 2021
Kind
B2
Abstract

The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient.

Claims (15)

1. A validated photonumeric scale for rating the severity of cellulite in an affected area of a human subject, the photonumeric scale comprising:

3 to 10 images showing an affected area of one or more example patients, the affected area in each of the 3 to 10 images of the example patients corresponding to the location of the affected area of the human subject, wherein each of the 3 to 10 images has a different severity rating comprising a numerical value, description, or both, the severity rating being based on a combination of two or more characteristics of cellulite selected from the group consisting of the number, depth, size, width, diameter, and distribution of dimples; and

wherein the photonumeric scale was validated using a test-retest reliability analysis.

2. The scale of claim 1 , wherein the affected area is buttock.

3. The scale of claim 1 , wherein the scale comprises images showing an affected area of at least 2 example patients.

4. The scale of claim 1 , wherein the scale comprises 5 images.

5. The scale of claim 1 , wherein the affected area is thigh.

6. The scale of claim 1 , wherein the scale comprises an image showing an affected area having no evident cellulite and an image showing an affected area having severe cellulite.

7. The scale of claim 1 , comprising a CR-PCSS scale.

8. The scale of claim 1 , comprising a PR-PCSS scale.

9. The scale of claim 6 , wherein the image showing an affected area having no evident cellulite has a numerical value that is lower than the image showing an affected area having severe cellulite.

10. The scale of claim 9 , wherein the image showing an affected area having no evident cellulite has a numerical value of 0.

11. The scale of claim 10 , wherein the image showing an affected area having severe cellulite has a numerical value of 4.

12. The scale of claim 9 , wherein the image showing an affected area having no evident cellulite contains no dimples, no depressions, no raised areas, or any combination thereof.

13. The scale of claim 9 , wherein the image showing an affected area having severe cellulite contains numerous deep dimples or ridges that cover most of the affected area, numerous undulations with alternating areas of protuberances and depressions of severe depth, or both.

Assignments (10)
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 068031/0059 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 068031/0202 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ENDO GLOBAL AESTHETICS LIMITED; ENDO GLOBAL VENTURES; ENDO VENTURES BERMUDA LIMITED; ENDO VENTURES LIMITED; PALADIN LABS INC.
Reel/Frame 067221/0958 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ENDO GLOBAL AESTHETICS LIMITED; ENDO GLOBAL VENTURES; ENDO VENTURES BERMUDA LIMITED; ENDO VENTURES LIMITED; PALADIN LABS INC.
Reel/Frame 067216/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2024
From: ENDO VENTURES UNLIMITED COMPANY
To: OPERAND PHARMACEUTICALS III LIMITED
Reel/Frame 066732/0137 →
CHANGE OF NAME Recorded Mar 5, 2024
From: ENDO VENTURES LIMITED
To: ENDO VENTURES UNLIMITED COMPANY
Reel/Frame 066732/0396 →
CHANGE OF NAME Recorded Mar 5, 2024
From: OPERAND PHARMACEUTICALS III LIMITED
To: ENDO OPERATIONS LIMITED
Reel/Frame 066732/0413 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ENDO VENTURES LIMITED; ENDO GLOBAL VENTURES; PALADIN LABS INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0893 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 26, 2020
From: ENDO GLOBAL VENTURES; ENDO VENTURES LIMITED; PALADIN LABS INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 053548/0239 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2019
From: DAVIDSON, JEFFREY; MCLANE, MICHAEL; LIU, GENZHOU
To: ENDO VENTURES LIMITED
Reel/Frame 050199/0939 →
Continuity (4)
Provisional Application 62465622 · Mar 1, 2017
Provisional Application 62485705 · Apr 14, 2017
Provisional Application 62607188 · Dec 18, 2017
Related Publication 20180250217A1 · Sep 6, 2018